<DOC>
	<DOCNO>NCT02946879</DOCNO>
	<brief_summary>This study longer-term follow-up study patient administer AAV2/5-OPTIRPE65 Phase I/II , open label , non-randomised , two-centre , dose escalation trial adult child retinal dystrophy associate defect RPE65 . The study design collect data longer-term safety efficacy 9- , 12- , 18- , 24- , 36- , 48- 60-month time-points follow AAV2/5-OPTIRPE65 administration .</brief_summary>
	<brief_title>Long-Term Follow-Up Gene Therapy Study Leber Congenital Amaurosis OPTIRPE65 ( Retinal Dystrophy Associated With Defects RPE65 )</brief_title>
	<detailed_description>The follow study design collect data longer-term safety efficacy 9 , 12 , 18 , 24 , 36 , 48 60 month time-points follow AAV2/5-OPTIRPE65 administration OPTIRPE65 trial . Safety efficacy assess clinical examination investigation accord pre-defined schedule follow visit . The OPTIRPE65 trial on-going open-label , Phase I/II dose-escalation study determine safety efficacy subretinal administration Advanced Therapy Investigational Medicinal Product participants RPE65-related retinal dystrophy .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<mesh_term>Retinal Dystrophies</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Eye Diseases , Hereditary</mesh_term>
	<criteria>Are able give inform consent assent , without guidance parent/guardian appropriate . Were enrol treat prior openlabel , Phase I/II , dose escalation study involve intraocular administration AAV2/5OPTIRPE65 Are willing adhere protocol longterm follow Individuals exclude unwilling unable meet requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>